Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma

71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO Benefit also... | May 25, 2023

Related Keywords

Texas ,United States ,Tarrytown ,American ,Tammy Allen ,Regeneron Velocimmune ,Georged Yancopoulos ,Hans Lee ,L Andres Sirulnik ,Myeloma Clinical Research ,Clinical Sciences ,Twitter ,Regeneron Genetics Center ,Exchange Commission ,International Staging System ,American Society Of Clinical Oncology ,Regeneron Pharmaceuticals Inc ,Nasdaq ,Regeneron Velocimmune Technology ,Drug Administration ,University Of Texas Md Anderson Cancer Center ,American Society Of Hematology ,Clinical Oncology ,Annual Meeting ,Associate Professor ,Multiple Myeloma Clinical Research ,American Society ,Senior Vice President ,Fast Track Designation ,Chief Scientific Officer George ,Regeneron Genetics ,Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Nc Stock Exchange ,News ,Information ,Press Release ,Objective ,Response ,Ith ,F ,Patients ,Chieving ,Very ,Wood ,Artial ,Dr ,Setter ,It ,The ,Ecommended ,00 ,G ,Her ,Few ,Data ,O ,He ,Shared ,N ,Mural ,Session ,Disco ,Enefit Regn Us75886f1075 ,